FDA Brief

Warning letters Drugs

FDA warning letter to

CareFusion 213, LLC

High riskIssued Apr 30Posted May 5Center for Drug Evaluation and Research (CDER)

FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.

What happened

FDA inspected CareFusion 213's drug manufacturing facility in El Paso, Texas, from October 15 to 24, 2025. FDA found inadequate investigations of more than 2,500 complaints since September 2023 and of an out-of-specification sterility failure that led to a recall. Investigators also found missing ongoing spore verification for biological indicators and cleaning and contamination-control failures, including residue, bioburden with Streptococcus pneumoniae, and environmental monitoring excursions.

What FDA found

  1. The firm failed to thoroughly investigate more than 2,500 customer complaints and did not extend investigations to other potentially affected batches.

    21 CFR 211.192
  2. The firm's investigation and corrective actions for an out-of-specification sterility failure were inadequate and did not properly extend to other lots of the packaging material.

    21 CFR 211.192
  3. The firm lacked ongoing quantitative verification of spore populations on in-house biological indicators used to verify sterilization and release product.

    21 CFR 211.160(b)
  4. Cleaning and maintenance were inadequate, with residue found in sterilization chambers and on vents, walls, and equipment despite cleaning logs.

    21 CFR 211.67(b)
  5. Contamination controls were inadequate, including improper gowning, a bioburden excursion with Streptococcus pneumoniae, and environmental monitoring excursions in filling areas.

    21 CFR 211.42(c)

What FDA wants

FDA asks CareFusion to provide comprehensive independent assessments and remediation plans for its complaint, CAPA, OOS, biological indicator, cleaning, and bioburden programs, along with retrospective reviews and process capability data. No response deadline is stated in the letter.

Who should pay attention

  • hospitals and clinics using sterile CareFusion/BD drug products
  • distributors and buyers of sterile drug products from this plant
  • quality teams responsible for sterile manufacturing, complaints, and CAPA

This is a summary. Read the original letter on fda.gov.

CareFusion 213, LLC's FDA history

Recalls in the last 12 months

Jul 22 Class II CareFusion 213, LLC
Drug
BD ChloraPrep Clear, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol), 60 x 1 mL applicators/carton, 0.03fl oz (1 mL) each, STERILE SOLUTION, CareFusion 123, LLC, El Paso, TX, subsidiary of Beckton, D…
Lack of Assurance of Sterility: Affected product may exhibit an open or incomplete seal on the packaging of the applicator
Jul 8 Class II CareFusion 213, LLC
Drug
BD ChloraPrep Hi-Lite Orange, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)), packaged as a) 100 x 10.5 mL applicators/case, NDC 54365-400-35, Catalog Number: 930715NS; b) 100 x 10.5 mL applic…
Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Jul 8 Class II CareFusion 213, LLC
Drug
ChloraPrep FREPP, Clear, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol) 500 x 1.5 mL applicators/case, STERILE SOLUTION, CareFusion 123, LLC, El Paso, TX, subsidiary of Beckton, Dickson and Co. NDC …
Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Jul 8 Class II CareFusion 213, LLC
Drug
BD ChloraPrep CLear, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol) 100 x 10.5 mL Applicators/case, STERILE SOLUTION, CareFusion 123, LLC, El Paso, TX, subsidiary of Beckton, Dickson and Co. NDC 543…
Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Jul 8 Class II CareFusion 213, LLC
Drug
BD ChloraPrep CLear, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol),500 x 1 mL applicators/case, STERILE SOLUTION, CareFusion 123, LLC, El Paso, TX, subsidiary of Beckton, Dickson and Co. NDC 54365…
Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Jul 8 Class II CareFusion 213, LLC
Drug
BD ChloraPrep Scrub Teal, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol) packaged as a) 25 x 26 mL applicators/case, NDC 54365-400-39, catalog number 930825NS, b) 50 x 26 mL applicators/case, NDC 5…
Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Jul 8 Class II CareFusion 213, LLC
Drug
BD PurPrep, (Povidone-iodine 8.3% w/w (0.83% available iodine) with isopropyl alcohol 72.5% w/w), 50 x 26 mL Applicator/case, STERILE SOLUTION, CAREFUSION 213, LLC, EL PASO, TX 79912, subsidiary of Beckton, Dickson and …
Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Jul 8 Class II CareFusion 213, LLC
Drug
BD ChloraPrep Hi-Lite Orange, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol) packaged as a) 100 x 3 mL applicators/case, NDC 54365-400-33, calatog 930415NS: b) 250 x 3mL applicators/case, bulk catal…
Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Jul 8 Class II CareFusion 213, LLC
Drug
BD ChloraPrep Scrub Teal, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol) packaged as a) 100 x 10.5 mL Applicators/case, NDC 54365-400-36, catalog number 930725NS; b) 100 x 10.5 mL Applicators/case, …
Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Jul 8 Class II CareFusion 213, LLC
Drug
BD ChloraPrep Hi-Lite Orange, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol) packaged as: a) 25 x 26 mL applicators/case, NDC 54365-400-38, calatog number 930815NS: b) 50 x 26 mL appliactors/case, b…
Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Jul 8 Class II CareFusion 213, LLC
Drug
BD ChloraPrep Clear, (2% w/v chlorhexidine gluconate (CHG), and 70% v/v isopropyl alcohol (IPA), Packaged as a) 100 x 3ml applicators/case, NDC 54365-400-32, catalog 930400NS; b) 250 x 3ml applicators/case, NDC 54365-400…
Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to customers outside of the intended distribution channel
Jul 1 Class II CareFusion 213, LLC
Drug
BD ChloraPrep Clear, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA) 1 mL Applicator, 60 Applicators, Sterile Solution, Care Fusion 213, LLC, El Paso, TX 79912, subsidiary of Beckton, Dickinson …
Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the seal area.
Jul 1 Class II CareFusion 213, LLC
Drug
BD ChloraPrep FREPP Clear, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA) 1.5 mL Applicator, 20 Applicators, Sterile Solution, Care Fusion 213, LLC, El Paso, TX 79912, subsidiary of Beckton, D…
Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the seal area.
Jul 1 Class I CareFusion 213, LLC
Drug
BD ChloraPrep Clear (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)), 1 mL Applicator, 60 Applicators per inner Carton, Sterile Solution, Care Fusion 213, LLC, El Paso, TX 79912, subsidiary of B…
Non-Sterility: Due to presence of Aspergillus penicillioides.
Jul 1 Class I CareFusion 213, LLC
Drug
BD ChloraPrep FREPP Clear,(2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA)) 1.5 mL Applicator, 20 Applicators, Sterile Solution, Care Fusion 213, LLC, El Paso, TX 79912, subsidiary of Beckton, Di…
Non-Sterility: Due to presence of Aspergillus penicillioides. And Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the seal area.
May 13 Class II CareFusion 213, LLC
Drug
BD PurPrep, Povidone-iodine 8.3% w/w (0.83% available iodine) with isopropyl alcohol 72.5% w/w Sterile Solution, 0.36 fl. oz. (10.5 mL) x 25 applicators per box. Carefusion 213, LLC, El Paso, TX 79912, subsidary of Becto…
Lack of assurance of Sterility: potential product contamination
May 13 Class II CareFusion 213, LLC
Drug
BD PurPrep, Povidone-iodine 8.3% w/w (0.83% available iodine) with isopropyl alcohol 72.5% w/w Sterile Solution, 25x26mL Applicators per carton. Carefusion 213 LLC, El Paso, TX 79912, NDC 54365-014-42.
Lack of assurance of Sterility: potential product contamination
Jan 7 Class II CareFusion 213, LLC
Drug
BD ChloraPrep" Triple Swabsticks (Chlorhexidine gluconate (CHG), 2% w/v and Isopropyl alcohol (IPA), 70% v/v), 5.25 mL Applicator, CareFusion 213, LLC, El Paso, TX 79912, NDC 54365-401-29
Lack of Assurance of Sterlity

Full company page

Similar letters to other companies

  1. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk
  2. Sciarra Aeromed, Inc.

    Sciarra Aeromed's purportedly sterile veterinary drug was contaminated and made under insanitary conditions, FDA says.

    High risk
  3. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  4. Bausch & Lomb Inc.

    FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.

    High risk